Blueprint Medicines Corporation (BPMC)

Blueprint Medicines Stock Forecast

Stock Price Forecast

The 20 analysts that cover Blueprint Medicines stock have a consensus rating of "Buy" and an average price target of $127.82, which forecasts a -1.21% decrease in the stock price over the next year. The lowest target is $105 and the highest is $138.

Price Target: $127.82 (-1.21%)

Analyst Consensus: Buy

Target	Low	Average	Median	High
Price	$105	$127.82	$129	$138
Change	-18.85%	-1.21%	-0.30%	+6.65%

Analyst Ratings

The average analyst rating for Blueprint Medicines stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.

Recommendation Trends

Rating	Feb '25	Mar '25	Apr '25	May '25	Jun '25	Jul '25
Strong Buy	6	7	6	6	4	4
Buy	7	8	8	8	2	2
Hold	5	6	6	6	14	14
Sell	0	0	0	0	0	0
Strong Sell	1	1	1	1	0	0
Total	19	22	21	21	20	20

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Derek Archila Wells Fargo	Wells Fargo	Buy → Hold Downgrades $143 → $129	Buy → Hold	Downgrades	$143 → $129	-0.30%	Jun 17, 2025
Judah Frommer Morgan Stanley	Morgan Stanley	Hold Maintains $102 → $129	Hold	Maintains	$102 → $129	-0.30%	Jun 5, 2025
David Dai UBS	UBS	Hold Maintains $88 → $129	Hold	Maintains	$88 → $129	-0.30%	Jun 5, 2025
David Lebowitz Citigroup	Citigroup	Strong Sell → Hold Upgrades $83 → $129	Strong Sell → Hold	Upgrades	$83 → $129	-0.30%	Jun 4, 2025
Reni Benjamin JMP Securities	JMP Securities	Buy → Hold Downgrades n/a	Buy → Hold	Downgrades	n/a	n/a	Jun 3, 2025

More Analyst Ratings

Financial Forecast

Revenue This Year

735.04M

Increased by 44.46%

from 508.82M

Revenue Next Year

975.99M

Increased by 32.78%

from 735.04M

EPS This Year

-0.91

from -1.07

EPS Next Year

1.04

from -0.91

Fiscal Year	FY 2020	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026	FY 2027
Period Ending	Dec 31, 2020	Dec 31, 2021	Dec 31, 2022	Dec 31, 2023	Dec 31, 2024	Dec 31, 2025	Dec 31, 2026	Dec 31, 2027
Revenue	793.74M	180.08M	204.04M	249.38M	508.82M	735.04M	975.99M	1.21B
Revenue Growth	1,093.37%	-77.31%	13.30%	22.22%	104.04%	44.46%	32.78%	24.08%
EPS	5.59	-11.01	-9.35	-8.37	-1.07	-0.91	1.04	4.16
EPS Growth	-	-	-	-	-	-	-	300.71%
Forward PE	-	-	-	-	-	-	124.55	31.08
No. Analysts	-	-	-	-	-	23	23	20

Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.

Revenue Forecast

Revenue	2025	2026	2027	2028	2029
High	811.7M	1.1B	1.4B
Avg	735.0M	976.0M	1.2B
Low	692.4M	841.8M	904.4M

Revenue Growth

Revenue Growth	2025	2026	2027	2028	2029
High	59.5%	45.0%	47.6%
Avg	44.5%	32.8%	24.1%
Low	36.1%	14.5%	-7.3%

EPS Forecast

EPS	2025	2026	2027	2028	2029
High	1.24	3.22	7.52
Avg	-0.91	1.04	4.16
Low	-2.05	-1.92	1.56

EPS Growth

EPS Growth	2025	2026	2027	2028	2029
High	-	-	623.7%
Avg	-	-	300.7%
Low	-	-	50.0%

Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.